BriaCell Therapeutics Corp. ( BCTX) Stock. Should you Buy or Sell? $ 8.07
-0.24 (-3.07 %)
BriaCell Therapeutics Corp. Analysis
Updated on 10-09-2022| Symbol | BCTX |
| Price | $8.07 |
| Beta | 1.376 |
| Volume Avg. | $378.99 thousand |
| Market Cap | $126.33 M |
| 52 Week Range | $4.06 - $12.47 |
BriaCell Therapeutics Corp. opened the day at $8.07 which is -3.07 % on yesterday's close. BriaCell Therapeutics Corp. has a 52 week high of $12.47 and 52 week low of $4.06, which is a difference of $8.41. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $126.33 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy BriaCell Therapeutics Corp. for $126.33 M, it would take 15 years to get your money back. BriaCell Therapeutics Corp. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
BriaCell Therapeutics Corp. Stock Forecast - Is BriaCell Therapeutics Corp. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -8.973 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing BriaCell Therapeutics Corp.
| Price Book Value Ratio | 2.705 | Price To Book Ratio | 2.705 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -8.973 |
How liquid is BriaCell Therapeutics Corp.
| Current Ratio | 126.202 |
| Quick Ratio | 121.602 |
Debt
| Debt Ratio | 0.014 | Debt Equity Ratio | 0.014 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about BriaCell Therapeutics Corp.
BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer. Bria-IMT is a cell-based immunotherapy.
The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which represents 10% of its public market securities.
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or dry cleaner, imagine the impact of losing a company that had devoted itself to enhancing the lives of women with breast cancer.
About BriaCell Therapeutics Corp.
Description :
BriaCell Therapeutics Corp., a clinical stage immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to investigate the mechanism of action of novel off-the-shelf personalized therapeutics for cancer. The company is headquartered in West Vancouver, Canada.
